Stock Events

Stock Events

LeonaBio 

$10.67
0
+$0.01+0.09% Today

Statistics

Day High
11.35
Day Low
10.67
52W High
-
52W Low
-
Volume
25
Avg. Volume
-
Mkt Cap
42.08M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Next
-2.5
-2.02
-1.54
-1.06
Expected EPS
-2.5022
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-193.88MNet Income

Analyst Ratings

$10.00Average Price Target
The highest estimate is 10.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LONA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap26.03B
Biogen is a leading biotech company focusing on neurodegenerative diseases, directly competing with Athira Pharma's focus on Alzheimer's and other neurological disorders.
Lilly(Eli) &
LLY
Mkt Cap837.36B
Eli Lilly has a strong pipeline in Alzheimer's disease treatments, making it a direct competitor to Athira Pharma in the neurodegenerative disease space.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.78B
ACADIA Pharmaceuticals focuses on the development of drugs to treat central nervous system disorders, competing with Athira Pharma in the neurology and psychiatry treatment market.
AnaptysBio
ANAB
Mkt Cap1.66B
AnaptysBio is engaged in developing therapeutic antibodies for the treatment of neuroinflammatory diseases, positioning it as a competitor in the neurodegenerative disease market.
Anavex Life Sciences
AVXL
Mkt Cap277.09M
Anavex Life Sciences Corp. specializes in the development of novel therapeutics for the treatment of Alzheimer's disease, Parkinson's, and other central nervous system diseases.
Prothena
PRTA
Mkt Cap530.79M
Prothena Corporation plc is a biotechnology company focused on the discovery and development of novel therapies for neurodegenerative diseases, including Alzheimer's.
Axsome Therapeutics
AXSM
Mkt Cap8.62B
Axsome Therapeutics, Inc. is developing novel therapies for central nervous system (CNS) disorders, including cognitive disorders related to Alzheimer's disease.
Arbutus Biopharma
ABUS
Mkt Cap875.74M
Arbutus Biopharma Corporation is slightly less directly competitive but is involved in the development of therapies for viral diseases and associated neurodegenerative conditions.

About

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Show more...
CEO
Dr. Mark J. Litton M.B.A., Ph.D.
Employees
26
Country
US
ISIN
US04746L2034

Listings

F
DE
6AI.F
XNAS
US
LONA
XNAS
US
ATHA
BOATS
BOATS
LONA.BOATS

0 Comments

Share your thoughts

FAQ

What is LeonaBio stock price today?▼
The current price of LONA.BOATS is $10.67 USD — it has increased by +0.09% in the past 24 hours. Watch LeonaBio stock price performance more closely on the chart.
What is LeonaBio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange LeonaBio stocks are traded under the ticker LONA.BOATS.
What is LeonaBio market cap?▼
Today LeonaBio has the market capitalization of 42.08M
When is the next LeonaBio earnings date?▼
LeonaBio is going to release the next earnings report on May 07, 2026.
What were LeonaBio earnings last quarter?▼
LONA.BOATS earnings for the last quarter are -1.68 USD per share, whereas the estimation was -1.06 USD resulting in a -58.49% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is LeonaBio revenue for the last year?▼
LeonaBio revenue for the last year amounts to 0 USD.
What is LeonaBio net income for the last year?▼
LONA.BOATS net income for the last year is -193.88M USD.
How many employees does LeonaBio have?▼
As of April 07, 2026, the company has 26 employees.
In which sector is LeonaBio located?▼
LeonaBio operates in the Health Care sector.
When did LeonaBio complete a stock split?▼
LeonaBio has not had any recent stock splits.
Where is LeonaBio headquartered?▼
LeonaBio is headquartered in Bothell, US.